Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-05-20Clinical Trial Update: Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Velcade (bortezomib) in combination with rituximab for relapsed/refractory mantle cell lymphoma and follicular no…
-
CLINICAL_TRIALS trial_result · 2014-05-19Clinical Trial Update: Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer [Phase 3]
Phase 3 trial evaluating total-body irradiation with or without fludarabine phosphate followed by donor stem cell transplant in hematologic …
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]
Phase 2 trial evaluating SDX-105 in combination with Rituxan for relapsed indolent or mantle cell Non-Hodgkin's Lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-04-29Clinical Trial Update: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia [Phase 1]
Phase 1 study of MK-2206 in pediatric patients with recurrent or refractory solid tumors or leukemias has completed.
-
CLINICAL_TRIALS trial_result · 2014-04-28Clinical Trial Update: Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study [Phase 3]
Phase 3 trial comparing bendamustine plus rituximab to R-CVP or R-CHOP in first-line advanced indolent non-Hodgkin's lymphoma or mantle cell…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-04-24Clinical Trial Update: Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma [Phase 2]
A Phase II trial evaluating chemotherapy followed by Zevalin (ibritumomab tiuxetan) for relapsed mantle cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-04-08Clinical Trial Update: Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating iodine-131 labeled anti-B1 antibody with CHOP for untreated mantle cell lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2014-04-04Clinical Trial Update: Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) [Phase 3]
Phase 3 trial evaluating the effect of bendamustine in combination with rituximab on QT interval in patients with advanced indolent non-Hodg…
-
CLINICAL_TRIALS trial_result · 2014-04-03Clinical Trial Update: CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 study of temsirolimus (CCI-779) for recurrent mantle cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-04-01Clinical Trial Update: Bortezomib in Treating Patients With Lymphoproliferative Disorders [Phase 2]
Phase 2 study of bortezomib in recurrent lymphoproliferative disorders, including follicular lymphoma and mantle cell lymphoma; results were…
-
CLINICAL_TRIALS trial_result · 2014-03-11Clinical Trial Update: CART-19 Immunotherapy in Mantle Cell Lymphoma [Phase 1, Phase 2]
This clinical trial update reports a CART-19 immunotherapy being evaluated in Phase 1/2 for Mantle Cell Lymphoma, with the trial status curr…
-
CLINICAL_TRIALS trial_result · 2014-03-05Clinical Trial Update: Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat [Phase 1]
This is a Phase 1b trial update of AMG 655 in combination with bortezomib or vorinostat for lymphomas, including Hodgkin lymphoma and variou…
-
CLINICAL_TRIALS trial_result · 2014-02-27Clinical Trial Update: Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 2]
This update reports results from a Phase 2 trial of ixabepilone in relapsed or refractory aggressive non-Hodgkin lymphoma across multiple su…
-
CLINICAL_TRIALS trial_result · 2014-02-24Clinical Trial Update: Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Phase 1]
Phase 1 trial evaluating the combination of tanespimycin and bortezomib in adults with advanced solid tumors or lymphomas; the study was ter…
-
CLINICAL_TRIALS trial_result · 2014-02-20Clinical Trial Update: Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating bortezomib and lenalidomide in relapsed or refractory mantle cell lymphoma has completed with results posted.
-
FDA approval · 2014-02-12FDA Approved: IMBRUVICA — Original Application (Pharmacyclics LLC)
The FDA granted the original approval of Imbruvica (ibrutinib) to Pharmacyclics LLC under NDA205552, marking its first approval for mantle c…
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating CCI-779 (temsirolimus) in patients with recurrent or refractory B-cell non-Hodgkin lymphoma or chronic l…
-
CLINICAL_TRIALS trial_result · 2014-01-28Clinical Trial Update: Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating a regimen of Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium-90 ibritumomab tiuxetan…
-
CLINICAL_TRIALS trial_result · 2014-01-22Clinical Trial Update: CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 results for the combination of temsirolimus (CCI-779) and rituximab in relapsed or refractory non-Hodgkin lymphoma have been reporte…
-
CLINICAL_TRIALS trial_result · 2014-01-03Clinical Trial Update: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy [EARLY_Phase 1]
A Phase 1 study evaluating the safety and tolerability of combining sirolimus with Hyper-CVAD chemotherapy in adults with lymphoid malignanc…
-
CLINICAL_TRIALS trial_result · 2013-12-18Clinical Trial Update: Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma [Phase 2]
A Phase 2 study evaluating chemotherapy with or without Rituximab in mantle cell lymphoma has completed. The update notes the trial compared…
-
FDA approval · 2013-11-13FDA Approved: IMBRUVICA — Original Application (Pharmacyclics LLC)
FDA approved IMBRUVICA (ibrutinib) under its Original Application (NDA205552) for mantle cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…
-
CLINICAL_TRIALS research · 2013-09-17Clinical Trial Update: Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma [Phase 3]
Phase 3 clinical trial comparing chemotherapy followed by radiation therapy and peripheral stem cell transplant versus chemotherapy plus int…
-
CLINICAL_TRIALS trial_result · 2013-09-09Clinical Trial Update: A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial [Phase 2]
Phase 2 trial assessing lenalidomide for mantle cell lymphoma after bortezomib failure or progression; results posted in 2013.